Empowering the next generation of HealthTech & AI startups.
A global venture studio driving the next wave of AI, HealthTech innovation, and impact investing.
HealthTech innovation is broken
An inefficient system, failed models, and unsupported founders — a structural gap the studio model is built to close.
- $9.8T in global health spending (2022) — ~9.9% of GDP.
- 20–40% of that spend wasted through inefficiency.
- ~4.5B people lack access to essential health services.
- ~75% fail to return capital to investors.
- 30–40% liquidate entirely.
- Only ~30–40% reach Series A after seed.
- Up to 90% of startups fail within their first few years.
- Founders spend ~60% of their time on non-core tasks.
- Isolation limits focus on product & market.
An integrated engine to create and scale ventures
We combine capital, talent, and shared infrastructure to build, validate, and scale startups — reducing risk and time-to-market while raising success rates.
Idea Sourcing
Identify data-backed healthcare opportunities.
Venture Building
Form teams, develop MVPs in-house.
Validation
Test, refine, and secure co-investment.
Spin-out
Launch as an independent startup with studio support.
Scale / Exit
Continued backing, partnerships, and eventual exit.
Average IRR
Venture studios vs. 21.3% for traditional VC funds.
Reach Series A
Studio-born ventures vs. 42% of traditional startups.
Time to Series A
Versus 56 months on the traditional path.
Riding two trillion-dollar curves
- $23B healthcare VC funding in 2024.
- 30% of deals involve AI-powered startups.
- Mature ecosystem — ideal base for scaling.
- Healthcare spend reaching $283B by 2026.
- Digital health adoption growing 20%+ CAGR.
- Early-stage capital gap — open window.
- Healthcare market reaching $259B by 2030.
- E-health funding grew 2.6× in 2020–2024.
- Just 3% of global AI funding — untapped.
A dynamic equity model aligned with contribution
Ownership reflects each venture's origin and the depth of studio involvement — fairness for founders, reward for in-house innovation.
Jointly developed with external founders using the studio's funding, infrastructure, and mentorship.
Built entirely within GVB — proprietary ideas, research, and execution owned and managed by the studio.
30–80% in every venture, realized through exits, acquisitions, and secondary sales.
Steady cash flow from shared teams and infrastructure — reducing dependency on exits.
Revenue from co-development, R&D partnerships, and licensing proprietary tech.
Multiple exit paths, and founders we never leave alone
- Strategic M&A, secondary / buybacks, and fund-level realizations.
- Cross-border studios historically add +32% IRR.
- Early-entrant emerging-market deals deliver ~2.1× higher ROI on first exits.
- Studio portfolios have produced $9B+ in follow-on funding.
- Coached founders are 2.5× more likely to hit key milestones.
- Access to 100+ mentors across health, tech, and business.
- Confidential counseling — 72% of founders report stress.
- A global peer network of 50+ founders per batch.
To fund Global Venture Builder's operations and portfolio creation across the U.S., Brazil, and Africa.
Studio Operations Fund
Core infrastructure, a global team, and shared resources.
Startups Creation Fund
Build and scale 8 AI-healthcare ventures (~$1.5M each).
- 8 high-potential AI-health startups built & validated within 25 months.
- 20–40% equity stake retained per startup.
- 5–6 ventures expected to reach Series A in the first cycle.
- Projected fund-level IRR of 25–30% on comparable benchmarks.
Led by experts with proven excellence
Hamed Salah
A due diligence and investor relations expert driving venture scale-up and strategic partnerships across the Middle East & Africa.
Noah Berman
An impact investor and serial entrepreneur aligned with global governance, scaling health & wellness ventures.